Leo Pharma

Last updated on 2006-02-21T08:10+0300.

About this image

sign

Quotes... Extracted quotes from

Leo Pharma added ( about Leo Pharma ) : "LEO Pharma has been working very closely with the UNION team and have been impressed with their approach and professionalism in dermatological drug development. Accordingly, when the strategic decision was taken to divest the LEO PDE4 inhibitor compound series and orismilast, UNION was an obvious partner of choice for LEO Pharma. We look forward to seeing the program moving forward for the benefit of patients in need of new treatment options" External link

news-yahoo Tuesday, July 21, 2020 9:55:00 AM EAT

Leo Pharma commented ( about Leo Pharma ) : “2019 was a significant year for LEO Pharma with a solid clinical and financial performance. With an underlying growth of 7%, we met expectations and a strong fourth quarter gives us confidence for 2020. At the same time, we made significant progress with our transformation into an innovation-driven growth company. The tralokinumab phase 3 data enables us to soon file for marketing authorization in US, Europe and Japan, and we have progressed important projects and partnerships. With the improved profitability of our established business we are well positioned to continue the transformation. Our overall results reflect these investments. Innovation is critical to LEO Pharma’s long-term success in dermatology which is among the three fastest growing therapeutic areas. On the back of clinical success in 2019 we will invest even more in our pipeline in 2020. We are building on a strong legacy towards our ambition to be the leader in terms of market position, breadth of portfolio and pipeline, and in how we enable patients to live healthy lives free of interference from their disease” External link

4-traders Friday, February 28, 2020 12:41:00 PM EAT

Leo Pharma said ( about Leo Pharma ) : “Today is a historic day for LEO Pharma. With the strong prescription dermatology brands and the new colleagues from Bayer, LEO Pharma advances significantly towards our goal of helping 125 million patients by 2025. We broaden our treatment range within the areas of acne, fungal skin infections and rosacea, as well as our range of topical steroids. By completing the final part of the acquisition, we considerably enhance our size in key markets like Brazil, Austria, and South Africa – underlining our ambition to become a world leader in medical dermatology” External link

bayer Thursday, July 4, 2019 6:40:00 PM EAT

Leo Pharma said ( about Leo Pharma ) : "Today is a historic day for LEO Pharma. With the strong prescription dermatology brands and the new colleagues from Bayer, LEO Pharma advances significantly towards our goal of helping 125 million patients by 2025. We broaden our treatment range within the areas of acne, fungal skin infections and rosacea, as well as our range of topical steroids. By completing the final part of the acquisition, we considerably enhance our size in key markets like Brazil, Austria, and South Africa - underlining our ambition to become a world leader in medical dermatology" External link

bayer Thursday, July 4, 2019 6:40:00 PM EAT

Leo Pharma dichiarato : “Oggi è un giorno storico. Ampliamo la nostra gamma di trattamenti nelle aree dell’acne, delle micosi cutanee e della rosacea, oltre alla nostra gamma di steroidi a uso topico. Al termine dell’acquisizione aumenteremo considerevolmente la nostra dimensione in mercati chiave quali il Brasile, l’Austria e il Sud Africa” External link

aboutpharma Tuesday, July 2, 2019 3:32:00 PM EAT

Leo Pharma said ( about Leo Pharma ) : “Today is a historic day for LEO Pharma. With the strong prescription dermatology brands and the new colleagues from Bayer, LEO Pharma advances significantly towards our goal of helping 125 million patients by 2025. We broaden our treatment range within the areas of acne, fungal skin infections and rosacea, as well as our range of topical steroids. By completing the final part of the acquisition, we considerably enhance our size in key markets like Brazil, Austria, and South Africa underlining our ambition to become a world leader in medical dermatology” External link

4-traders Tuesday, July 2, 2019 10:18:00 AM EAT



Key Titles and Phrases Count Lang Last Seen
Names Lang Count
Leo PharmaFR25.93%
Leo PharmaSV22.22%
Leo PharmaEN22.22%
Leo PharmaDA22.22%
LEO PharmaEN7.41%


 
Show/hide duplicate news articles.
<<10<12345678910>>>10
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Tools

Load latest edition

Friday, August 14, 2020

5:26:00 AM EAT

Languages Collapse menu...Expand menu...

Select your languages

af
am
ar
de
en
es
fr
ha
pt
rw
sw
all
Show additional languagesHide additional languages

Interface:

Legend Collapse menu...Expand menu...


Quotes... Explore Relations


EMM Visual Explorer


Quotes... Extracted quotes about

Leo Pharma added ( about Leo Pharma ) : "LEO Pharma has been working very closely with the UNION team and have been impressed with their approach and professionalism in dermatological drug development. Accordingly, when the strategic decision was taken to divest the LEO PDE4 inhibitor compound series and orismilast, UNION was an obvious partner of choice for LEO Pharma. We look forward to seeing the program moving forward for the benefit of patients in need of new treatment options" External link

news-yahoo Tuesday, July 21, 2020 9:55:00 AM EAT

Leo Pharma commented ( about Leo Pharma ) : “2019 was a significant year for LEO Pharma with a solid clinical and financial performance. With an underlying growth of 7%, we met expectations and a strong fourth quarter gives us confidence for 2020. At the same time, we made significant progress with our transformation into an innovation-driven growth company. The tralokinumab phase 3 data enables us to soon file for marketing authorization in US, Europe and Japan, and we have progressed important projects and partnerships. With the improved profitability of our established business we are well positioned to continue the transformation. Our overall results reflect these investments. Innovation is critical to LEO Pharma’s long-term success in dermatology which is among the three fastest growing therapeutic areas. On the back of clinical success in 2019 we will invest even more in our pipeline in 2020. We are building on a strong legacy towards our ambition to be the leader in terms of market position, breadth of portfolio and pipeline, and in how we enable patients to live healthy lives free of interference from their disease” External link

4-traders Friday, February 28, 2020 12:41:00 PM EAT

Kim Kjoeller said ( about Leo Pharma ) : “Data that LEO Pharma will present at EADV show how we continue to pioneer medical dermatology with the goal to constantly improve what is possible for patients,” External link

4-traders Wednesday, October 9, 2019 9:18:00 AM EAT

Leo Pharma said ( about Leo Pharma ) : “Today is a historic day for LEO Pharma. With the strong prescription dermatology brands and the new colleagues from Bayer, LEO Pharma advances significantly towards our goal of helping 125 million patients by 2025. We broaden our treatment range within the areas of acne, fungal skin infections and rosacea, as well as our range of topical steroids. By completing the final part of the acquisition, we considerably enhance our size in key markets like Brazil, Austria, and South Africa – underlining our ambition to become a world leader in medical dermatology” External link

bayer Thursday, July 4, 2019 6:40:00 PM EAT

Leo Pharma said ( about Leo Pharma ) : "Today is a historic day for LEO Pharma. With the strong prescription dermatology brands and the new colleagues from Bayer, LEO Pharma advances significantly towards our goal of helping 125 million patients by 2025. We broaden our treatment range within the areas of acne, fungal skin infections and rosacea, as well as our range of topical steroids. By completing the final part of the acquisition, we considerably enhance our size in key markets like Brazil, Austria, and South Africa - underlining our ambition to become a world leader in medical dermatology" External link

bayer Thursday, July 4, 2019 6:40:00 PM EAT

Leo Pharma said ( about Leo Pharma ) : “Today is a historic day for LEO Pharma. With the strong prescription dermatology brands and the new colleagues from Bayer, LEO Pharma advances significantly towards our goal of helping 125 million patients by 2025. We broaden our treatment range within the areas of acne, fungal skin infections and rosacea, as well as our range of topical steroids. By completing the final part of the acquisition, we considerably enhance our size in key markets like Brazil, Austria, and South Africa underlining our ambition to become a world leader in medical dermatology” External link

4-traders Tuesday, July 2, 2019 10:18:00 AM EAT

Jason Norris said ( about Leo Pharma ) : "We are excited to further our partnership with LEO Pharma, who we consider to be a leader in patient centric innovation. This flagship deal for our growing company is an exciting consummation of a close partnership over the last 2 years. The biopharma industry's continued shift to subcutaneous administration is a reflection of patients' demand for convenience. Elektrofi is thrilled to utilize its technology with LEO Pharma to improve patients' lives," External link

finanznachrichten-en Tuesday, April 9, 2019 12:24:00 PM EAT

Kim Kjoeller said ( about Leo Pharma ) : “At LEO Pharma, we work relentlessly to help patients with skin diseases. We are driven by our desire to offer new, innovative medicines better and faster than anyone else, and our aspiration is to help 125 million patients by 2025. The addition of the new unit in Boston will boost our position in Translational Medicine and help us achieve exactly that. It will strengthen LEO Pharma as a science driven organization by increasing our level of science and dermatology knowledge and thus enable us to explore cutting edge technologies in patients more rapidly,” External link

4-traders Monday, January 28, 2019 12:39:00 PM EAT

Kim Kjoeller said ( about Leo Pharma ) : "At LEO Pharma, we work relentlessly to help patients with skin diseases. We are driven by our desire to offer new, innovative medicines better and faster than anyone else, and our aspiration is to help 125 million patients by 2025. The addition of the new unit in Boston will boost our position in Translational Medicine and help us achieve exactly that. It will strengthen LEO Pharma as a science driven organization by increasing our level of science and dermatology knowledge and thus enable us to explore cutting edge technologies in patients more rapidly," External link

finanznachrichten-en Monday, January 28, 2019 12:38:00 PM EAT

Luke Miels dijo ( about Leo Pharma ) : “Este acuerdo nos permite concentrarnos en el potencial de tralokinumab para pacientes con asma severa, un área prioritaria para AstraZeneca, mientras nos beneficiamos de la experiencia de Leo Pharma en dermatología para el desarrollo continuo y la comercialización de tralokinumab en dermatitis atópica y otras condiciones dermatológicas” External link

diariolibre-en Tuesday, July 5, 2016 7:20:00 AM EAT

AfricaBrief

Leo Pharma

Last updated on 2006-02-21T08:10+0300.

About this image

sign

Quotes... Extracted quotes from

Leo Pharma added ( about Leo Pharma ) : "LEO Pharma has been working very closely with the UNION team and have been impressed with their approach and professionalism in dermatological drug development. Accordingly, when the strategic decision was taken to divest the LEO PDE4 inhibitor compound series and orismilast, UNION was an obvious partner of choice for LEO Pharma. We look forward to seeing the program moving forward for the benefit of patients in need of new treatment options" External link

news-yahoo Tuesday, July 21, 2020 9:55:00 AM EAT

Leo Pharma commented ( about Leo Pharma ) : “2019 was a significant year for LEO Pharma with a solid clinical and financial performance. With an underlying growth of 7%, we met expectations and a strong fourth quarter gives us confidence for 2020. At the same time, we made significant progress with our transformation into an innovation-driven growth company. The tralokinumab phase 3 data enables us to soon file for marketing authorization in US, Europe and Japan, and we have progressed important projects and partnerships. With the improved profitability of our established business we are well positioned to continue the transformation. Our overall results reflect these investments. Innovation is critical to LEO Pharma’s long-term success in dermatology which is among the three fastest growing therapeutic areas. On the back of clinical success in 2019 we will invest even more in our pipeline in 2020. We are building on a strong legacy towards our ambition to be the leader in terms of market position, breadth of portfolio and pipeline, and in how we enable patients to live healthy lives free of interference from their disease” External link

4-traders Friday, February 28, 2020 12:41:00 PM EAT

Leo Pharma said ( about Leo Pharma ) : “Today is a historic day for LEO Pharma. With the strong prescription dermatology brands and the new colleagues from Bayer, LEO Pharma advances significantly towards our goal of helping 125 million patients by 2025. We broaden our treatment range within the areas of acne, fungal skin infections and rosacea, as well as our range of topical steroids. By completing the final part of the acquisition, we considerably enhance our size in key markets like Brazil, Austria, and South Africa – underlining our ambition to become a world leader in medical dermatology” External link

bayer Thursday, July 4, 2019 6:40:00 PM EAT

Leo Pharma said ( about Leo Pharma ) : "Today is a historic day for LEO Pharma. With the strong prescription dermatology brands and the new colleagues from Bayer, LEO Pharma advances significantly towards our goal of helping 125 million patients by 2025. We broaden our treatment range within the areas of acne, fungal skin infections and rosacea, as well as our range of topical steroids. By completing the final part of the acquisition, we considerably enhance our size in key markets like Brazil, Austria, and South Africa - underlining our ambition to become a world leader in medical dermatology" External link

bayer Thursday, July 4, 2019 6:40:00 PM EAT

Leo Pharma dichiarato : “Oggi è un giorno storico. Ampliamo la nostra gamma di trattamenti nelle aree dell’acne, delle micosi cutanee e della rosacea, oltre alla nostra gamma di steroidi a uso topico. Al termine dell’acquisizione aumenteremo considerevolmente la nostra dimensione in mercati chiave quali il Brasile, l’Austria e il Sud Africa” External link

aboutpharma Tuesday, July 2, 2019 3:32:00 PM EAT

Leo Pharma said ( about Leo Pharma ) : “Today is a historic day for LEO Pharma. With the strong prescription dermatology brands and the new colleagues from Bayer, LEO Pharma advances significantly towards our goal of helping 125 million patients by 2025. We broaden our treatment range within the areas of acne, fungal skin infections and rosacea, as well as our range of topical steroids. By completing the final part of the acquisition, we considerably enhance our size in key markets like Brazil, Austria, and South Africa underlining our ambition to become a world leader in medical dermatology” External link

4-traders Tuesday, July 2, 2019 10:18:00 AM EAT



Key Titles and Phrases Count Lang Last Seen
Names Lang Count
Leo PharmaFR25.93%
Leo PharmaSV22.22%
Leo PharmaEN22.22%
Leo PharmaDA22.22%
LEO PharmaEN7.41%


<<10<12345678910>>>10
<<10<12345678910>>>10

Tools

Load latest edition

Friday, August 14, 2020

5:26:00 AM EAT


Quotes... Explore Relations


EMM Visual Explorer


Quotes... Extracted quotes about

Leo Pharma added ( about Leo Pharma ) : "LEO Pharma has been working very closely with the UNION team and have been impressed with their approach and professionalism in dermatological drug development. Accordingly, when the strategic decision was taken to divest the LEO PDE4 inhibitor compound series and orismilast, UNION was an obvious partner of choice for LEO Pharma. We look forward to seeing the program moving forward for the benefit of patients in need of new treatment options" External link

news-yahoo Tuesday, July 21, 2020 9:55:00 AM EAT

Leo Pharma commented ( about Leo Pharma ) : “2019 was a significant year for LEO Pharma with a solid clinical and financial performance. With an underlying growth of 7%, we met expectations and a strong fourth quarter gives us confidence for 2020. At the same time, we made significant progress with our transformation into an innovation-driven growth company. The tralokinumab phase 3 data enables us to soon file for marketing authorization in US, Europe and Japan, and we have progressed important projects and partnerships. With the improved profitability of our established business we are well positioned to continue the transformation. Our overall results reflect these investments. Innovation is critical to LEO Pharma’s long-term success in dermatology which is among the three fastest growing therapeutic areas. On the back of clinical success in 2019 we will invest even more in our pipeline in 2020. We are building on a strong legacy towards our ambition to be the leader in terms of market position, breadth of portfolio and pipeline, and in how we enable patients to live healthy lives free of interference from their disease” External link

4-traders Friday, February 28, 2020 12:41:00 PM EAT

Kim Kjoeller said ( about Leo Pharma ) : “Data that LEO Pharma will present at EADV show how we continue to pioneer medical dermatology with the goal to constantly improve what is possible for patients,” External link

4-traders Wednesday, October 9, 2019 9:18:00 AM EAT

Leo Pharma said ( about Leo Pharma ) : “Today is a historic day for LEO Pharma. With the strong prescription dermatology brands and the new colleagues from Bayer, LEO Pharma advances significantly towards our goal of helping 125 million patients by 2025. We broaden our treatment range within the areas of acne, fungal skin infections and rosacea, as well as our range of topical steroids. By completing the final part of the acquisition, we considerably enhance our size in key markets like Brazil, Austria, and South Africa – underlining our ambition to become a world leader in medical dermatology” External link

bayer Thursday, July 4, 2019 6:40:00 PM EAT

Leo Pharma said ( about Leo Pharma ) : "Today is a historic day for LEO Pharma. With the strong prescription dermatology brands and the new colleagues from Bayer, LEO Pharma advances significantly towards our goal of helping 125 million patients by 2025. We broaden our treatment range within the areas of acne, fungal skin infections and rosacea, as well as our range of topical steroids. By completing the final part of the acquisition, we considerably enhance our size in key markets like Brazil, Austria, and South Africa - underlining our ambition to become a world leader in medical dermatology" External link

bayer Thursday, July 4, 2019 6:40:00 PM EAT

Leo Pharma said ( about Leo Pharma ) : “Today is a historic day for LEO Pharma. With the strong prescription dermatology brands and the new colleagues from Bayer, LEO Pharma advances significantly towards our goal of helping 125 million patients by 2025. We broaden our treatment range within the areas of acne, fungal skin infections and rosacea, as well as our range of topical steroids. By completing the final part of the acquisition, we considerably enhance our size in key markets like Brazil, Austria, and South Africa underlining our ambition to become a world leader in medical dermatology” External link

4-traders Tuesday, July 2, 2019 10:18:00 AM EAT

Jason Norris said ( about Leo Pharma ) : "We are excited to further our partnership with LEO Pharma, who we consider to be a leader in patient centric innovation. This flagship deal for our growing company is an exciting consummation of a close partnership over the last 2 years. The biopharma industry's continued shift to subcutaneous administration is a reflection of patients' demand for convenience. Elektrofi is thrilled to utilize its technology with LEO Pharma to improve patients' lives," External link

finanznachrichten-en Tuesday, April 9, 2019 12:24:00 PM EAT

Kim Kjoeller said ( about Leo Pharma ) : “At LEO Pharma, we work relentlessly to help patients with skin diseases. We are driven by our desire to offer new, innovative medicines better and faster than anyone else, and our aspiration is to help 125 million patients by 2025. The addition of the new unit in Boston will boost our position in Translational Medicine and help us achieve exactly that. It will strengthen LEO Pharma as a science driven organization by increasing our level of science and dermatology knowledge and thus enable us to explore cutting edge technologies in patients more rapidly,” External link

4-traders Monday, January 28, 2019 12:39:00 PM EAT

Kim Kjoeller said ( about Leo Pharma ) : "At LEO Pharma, we work relentlessly to help patients with skin diseases. We are driven by our desire to offer new, innovative medicines better and faster than anyone else, and our aspiration is to help 125 million patients by 2025. The addition of the new unit in Boston will boost our position in Translational Medicine and help us achieve exactly that. It will strengthen LEO Pharma as a science driven organization by increasing our level of science and dermatology knowledge and thus enable us to explore cutting edge technologies in patients more rapidly," External link

finanznachrichten-en Monday, January 28, 2019 12:38:00 PM EAT

Luke Miels dijo ( about Leo Pharma ) : “Este acuerdo nos permite concentrarnos en el potencial de tralokinumab para pacientes con asma severa, un área prioritaria para AstraZeneca, mientras nos beneficiamos de la experiencia de Leo Pharma en dermatología para el desarrollo continuo y la comercialización de tralokinumab en dermatitis atópica y otras condiciones dermatológicas” External link

diariolibre-en Tuesday, July 5, 2016 7:20:00 AM EAT